Compass Pathways (Compass Pathways) EBITDA Margin % : 0.00% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Compass Pathways EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Compass Pathways's EBITDA for the three months ended in Mar. 2024 was $-33.81 Mil. Compass Pathways's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Compass Pathways's EBITDA margin for the quarter that ended in Mar. 2024 was 0.00%.

Compass Pathways EBITDA Margin % Historical Data

The historical data trend for Compass Pathways's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Compass Pathways EBITDA Margin % Chart

Compass Pathways Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBITDA Margin %

Get a 7-Day Free Trial

Compass Pathways Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBITDA Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Compass Pathways's EBITDA Margin %

For the Medical Care Facilities subindustry, Compass Pathways's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Compass Pathways's EBITDA Margin % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Compass Pathways's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Compass Pathways's EBITDA Margin % falls into.

Compass Pathways EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Compass Pathways's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-115.238	/	0
	=	%

Compass Pathways's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-33.806	/	0
	=	%

Compass Pathways (NAS:CMPS) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Compass Pathways EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Compass Pathways's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Compass Pathways (Compass Pathways) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Compass Pathways PLC (NAS:CMPS) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

5Y6:Germany

Address

33 Broadwick Street, London, GBR, W1F 0DQ

Website

https://www.compasspathways.com

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

Executives

Ekaterina Malievskaia	officer: Chief Innovation Officer	C/O COMPASS PATHWAYS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
George Jay Goldsmith	director, 10 percent owner, officer: Chief Executive Officer	C/O COMPASS PATHWAYS PLC, 1 ASHLEY ROAD, 3RD FLOOR, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Mary-rose Hughes	officer: Interim CFO	C/O COMPASS PATHWAYS PLC, 33 BROADWICK STREET, LONDON X0 W1F0DQ
Daphne Karydas	director	35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Kabir Nath	director, officer: Chief Executive Officer	C/O COMPASS PATHWAYS PLC, 33 BROADWICK STREET, LONDON X0 W1F 0DQ
Annalisa Jenkins	director	C/O ARDELYX, INC., 34715 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555
David Y Norton	director	8 GREENHOLM STREET, APT C, PRINCETON NJ 08540
Matthew A Owens	officer: General Counsel & CLO	1900 POLARIS PARKWAY, COLUMBUS OH 43240
Atai Life Sciences Ag	10 percent owner	KRAUSENSTRASSE 9-10, BERLIN 2M 10117
Atai Life Sciences N.v.	10 percent owner	524 BROADWAY, NEW YORK NY 10013
Linda Mcgoldrick	director	C/O AVADIM HEALTH, INC., 81 THOMPSON STREET, ASHEVILLE NC 28803
Jason Camm	director	C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014
Robert Mcquade	director	C/O COMPASS PATHWAYS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Michael Falvey	officer: Chief Financial Officer	C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, 2ND FLOOR, NEWTON MA 02459
Guy Goodwin	officer: Chief Medical Officer	C/O COMPASS PATHWAYS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT